Every 8-K that Rigel Pharmaceuticals Inc. (New) (RIGL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RIGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RIGL filings page.
Rigel Pharmaceuticals reported second quarter 2026 total revenues of $78.7 million, including record net product sales of $67.0 million, up 14% year over year, and $11.7 million of contract revenues from collaborations. Net income was $17.3 million, or $0.88 per diluted share.
Growth in product sales was led by TAVALISSE at $47.4 million (up 18%) and REZLIDHIA at $8.9 million (up 27%), while GAVRETO declined to $10.7 million. Collaboration revenue reflected $5.8 million from Kissei, $5.0 million from Grifols and $0.3 million from Medison; the prior-year quarter included $40.0 million of non-cash revenue from a Lilly cost-share release, which lowered year-over-year reported revenues and earnings. For the first half of 2026, total revenues were $137.5 million and net income was $25.9 million.
Rigel entered an exclusive global license with Arvinas and Pfizer for VEPPANU, paying a $70.0 million upfront payment and preparing for U.S. commercial availability in mid-August 2026. Cash, cash equivalents and short-term investments were $95.3 million at June 30, 2026. The company raised its 2026 total revenue outlook to $285–$295 million, including $255–$265 million in net product sales and about $30 million in contract revenues, excluding VEPPANU, and continues to anticipate positive full-year net income.
Rigel Pharmaceuticals announced a leadership change in its top medical role. Alison L. Hannah, M.D. has been appointed Executive Vice President and Chief Medical Officer, effective July 1, 2026. At the same time, she resigned from Rigel’s Board of Directors, where she had served since May 2021.
Dr. Hannah has worked as a consultant to the pharmaceutical and biotechnology industry since 2000, focusing on investigational cancer therapies, and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc. Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer and separated from Rigel effective June 25, 2026.
Rigel Pharmaceuticals, Inc. completed a major licensing transaction, making its License Agreement with Arvinas, Inc., Arvinas affiliates and Pfizer Inc. effective for VEPPANU™ (vepdegestrant). The deal grants Rigel exclusive, global rights to develop, manufacture and commercialize VEPPANU and related products worldwide.
Following early termination of the Hart-Scott-Rodino antitrust waiting period and satisfaction of closing conditions, Rigel closed the transaction and paid the licensors a one-time upfront payment of $70.0 million.
Rigel Pharmaceuticals reported results from its 2026 annual stockholder meeting. Stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares of common stock, respectively, for future equity grants and purchases.
All three director nominees were elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, executive compensation as described in the proxy statement and ratified Ernst & Young LLP as Rigel’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Rigel Pharmaceuticals has entered into an exclusive, royalty-bearing worldwide license agreement with Arvinas entities and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant) and related products. VEPPANU is approved in the United States for certain ER+, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer.
Rigel will pay an upfront $70 million, up to $15 million tied to transition activities, and up to $320 million in potential regulatory and sales milestone payments, plus tiered royalties from the mid‑teens to mid‑twenties on net sales. Rigel will lead global development and commercialization, while reimbursing specified ongoing development costs up to $40 million. The agreement becomes effective after expiration or termination of the applicable Hart‑Scott‑Rodino antitrust waiting period.
Rigel Pharmaceuticals reported first quarter 2026 total revenues of $58.8 million, driven by $54.9 million in net product sales and $3.9 million in contract revenues from collaborations. Net product sales rose 26% year over year, reflecting growth across its hematology-oncology portfolio.
TAVALISSE net product sales were $37.3 million, up 31%, GAVRETO reached $9.6 million, up 7%, and REZLIDHIA generated $8.0 million, up 31% versus the same period in 2025. Rigel posted net income of $8.7 million, or $0.47 basic and $0.44 diluted per share, compared with $11.4 million a year earlier, as total costs and expenses increased to $46.9 million on higher R&D and commercial spending.
Cash, cash equivalents and short-term investments were $146.7 million as of March 31, 2026. The company reaffirmed its 2026 outlook for total revenues of approximately $275–$290 million, including net product sales of $255–$265 million and contract revenues of $20–$25 million, and continues to anticipate positive full-year net income while funding ongoing clinical programs such as R289.
Rigel Pharmaceuticals reports that Eli Lilly and Company has elected to terminate their License and Collaboration Agreement covering ocadusertib (previously R552) and other RIPK1 inhibitors. Lilly’s termination is in its entirety and becomes effective June 15, 2026.
The agreement, signed on February 18, 2021, had granted Lilly an exclusive worldwide license to develop and commercialize RIPK1 inhibitors for non-CNS and CNS diseases, with potential milestone payments and royalties to Rigel. After termination, Lilly’s rights to the licensed compounds will cease, subject to transition provisions, and Rigel expects to regain full rights to these programs.
Rigel is evaluating the impact of the termination and, following this step and the earlier end of the CNS disease program effective in November 2025, does not expect to receive future milestones or royalties under the agreement.
Rigel Pharmaceuticals reported very strong fourth quarter and full-year 2025 results driven by its hematology and oncology portfolio. Fourth quarter 2025 total revenues were $69.8 million, with net product sales of $65.4 million, up 41% from 2024, and contract revenues of $4.4 million. Net income for the quarter surged to $268.1 million, or $13.54 diluted per share, largely reflecting a $245.9 million non-cash deferred income tax benefit.
For 2025, total revenues were $294.3 million, including $232.0 million of net product sales, which grew 60% year over year, and $62.3 million of contract revenues. Full-year net income was $367.0 million, or $19.48 diluted per share. Cash, cash equivalents and short-term investments increased to $155.0 million as of December 31, 2025, from $77.3 million a year earlier.
Rigel continues to advance its pipeline, particularly the Phase 1b study of R289 in lower-risk myelodysplastic syndrome, with dose expansion enrollment ongoing and recommended Phase 2 dose selection expected in the second half of 2026. For 2026, the company anticipates total revenues of $275 to $290 million and positive net income while funding existing and new clinical programs.
Rigel Pharmaceuticals, Inc. appointed Michael P. Miller to its board of directors effective February 1, 2026. He will serve in the director class whose term ends at the 2027 annual stockholders’ meeting and will also join the company’s Compensation Committee.
As a non-employee director, Mr. Miller will receive a yearly cash retainer of $50,000, plus an additional annual $10,000 retainer for Compensation Committee service, both pro-rated for partial service periods. He received an initial stock option grant to purchase 12,000 shares of common stock under Rigel’s 2018 Equity Incentive Plan.
After each annual stockholders’ meeting, he will automatically receive an annual option to purchase 3,000 shares of common stock and 2,500 restricted stock units, pro-rated for any year of partial service, so long as he continues to serve as a non-employee director. The company entered into its standard indemnification agreement with him and states that he is independent, has no disclosable related-party transactions, and no family relationships with the company’s directors or executive officers.
Rigel Pharmaceuticals, Inc. filed a current report to note that it has provided investors with preliminary, unaudited estimates of its financial results for the fourth quarter and full fiscal year ended December 31, 2025. These estimates are based on currently available information and do not include all details needed for a complete picture of the company’s financial condition or operating results for that period.
The company also disclosed that it issued a press release titled “Rigel Provides Business Update and 2026 Outlook,” which is included as Exhibit 99.1. That release contains a broader business update and the company’s outlook for 2026, and is incorporated by reference into this report.
Rigel Pharmaceuticals furnished a press release announcing its financial results for the third quarter ended September 30, 2025 and providing a business update. The press release was included as Exhibit 99.1.
The company specified that this information is furnished, not filed, and therefore is not subject to Section 18 liability and will not be incorporated by reference into other SEC filings.